Current targeted therapies in the treatment of advanced colorectal cancer: a review
Treatment strategies for metastatic colorectal cancer (mCRC) patients have undergone dramatic changes in the past decade and despite improved patient outcomes, there still exist areas for continued development. The introduction of targeted agents has provided clinicians with additional treatment opt...
Main Authors: | Andrew Moriarity, Jacintha O’Sullivan, John Kennedy, Brian Mehigan, Paul McCormick |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2016-07-01
|
Series: | Therapeutic Advances in Medical Oncology |
Online Access: | https://doi.org/10.1177/1758834016646734 |
Similar Items
-
Combining 1,4-dihydroxy quininib with Bevacizumab/FOLFOX alters angiogenic and inflammatory secretions in ex vivo colorectal tumors
by: Susan A. Kennedy, et al.
Published: (2020-10-01) -
Colonic oncostatin M expression evaluated by immunohistochemistry and infliximab therapy outcome in corticosteroid-refractory acute severe ulcerative colitis
by: Jim O’Connell, et al.
Published: (2022-07-01) -
Targeting cancer-cell mitochondria and metabolism to improve radiotherapy response
by: Emma McCann, et al.
Published: (2021-01-01) -
Assessing Circulating Tumour DNA (ctDNA) as a Biomarker for Anal Cancer Management: A Systematic Review
by: Hugo C. Temperley, et al.
Published: (2024-04-01) -
Gastrointestinal Stromal Tumours (GIST) of the Rectum: A Systematic Review and Meta-Analysis
by: Shaheer I. Khan, et al.
Published: (2022-12-01)